Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Spyre Therapeutics, Inc. - Common Stock (NQ:SYRE)

21.59 -0.80 (-3.60%)
Streaming Delayed Price Updated: 9:52 AM EST, Nov 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Spyre Therapeutics, Inc. - Common Stock

Domino's Pizza Posts Upbeat Results, Joins Astria Therapeutics, Albertsons Companies, Polaris And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
This United Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings... 
Via Benzinga
Spyre (SYRE) Q2 R&D Up 23% Loss Narrows
Via The Motley Fool
This Weyerhaeuser Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
 
Via Benzinga
SYRE Stock Earnings: Spyre Therapeutics Beats EPS for Q2 2024
SYRE stock results show that Spyre Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
SYRE Stock Earnings: Spyre Therapeutics Misses EPS for Q1 2024
SYRE stock results show that Spyre Therapeutics missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
NIO Reports Upbeat Earnings, Joins Dave, V2X, Riskified And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were lower, with the Dow Jones index falling more than 200 points on Tuesday. 
Via Benzinga
Topics Stocks
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.